Nanobiotix plummets after unfavorable EMA opinion
Nanobiotix shares fall 38% after a negative opinion from the European Medicines Agency.
Published 3sem1 sourceImportant
Lire en français
≈ 15s
The fact
The head and neck cancer treatment is deemed insufficient.
The company plans to appeal and review the data.
Click the link to read an article on the topic: